|
Telik's product development focus is on cancer. We currently have
two candidates in clinical development:
A cancer cell-activated small molecule in development for ovarian and non-small cell lung cancer. Learn
more about TELCYTA®
A small molecule bone marrow stimulant, is in a Phase 2 trial
in myelodysplastic syndrome. Learn
more about TELINTRA®
Additional potential product candidates in our pipeline
have resulted from our ongoing discovery research programs and our
collaborations with leading cancer centers. These include inhibitors of enzymes we
believe are critical to the growth of cancer cells, and MCP-1 inhibitors
that have potential for the treatment of cancer and inflammatory
diseases. View preclinical pipeline
|
